97 related articles for article (PubMed ID: 36033760)
1. Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study.
Qin S; Wang X; Li S; Tan C; Zeng X; Wu M; Peng Y; Wang L; Wan X
Front Public Health; 2022; 10():955120. PubMed ID: 36033760
[TBL] [Abstract][Full Text] [Related]
2. Effect and cost-effectiveness of national gastric cancer screening in Japan: a microsimulation modeling study.
Huang HL; Leung CY; Saito E; Katanoda K; Hur C; Kong CY; Nomura S; Shibuya K
BMC Med; 2020 Sep; 18(1):257. PubMed ID: 32921305
[TBL] [Abstract][Full Text] [Related]
3. Personalizing age of gastric cancer screening based on comorbidity in China: Model estimates of benefits, affordability and cost-effectiveness optimization.
Qin S; Wang X; Li S; Wu M; Wan X
Prev Med; 2024 Feb; 179():107851. PubMed ID: 38191061
[TBL] [Abstract][Full Text] [Related]
4. Risk-based lung cancer screening in heavy smokers: a benefit-harm and cost-effectiveness modeling study.
Liu Y; Xu H; Lv L; Wang X; Kang R; Guo X; Wang H; Zheng L; Liu H; Guo L; Chen Q; Liu S; Qiao Y; Zhang S
BMC Med; 2024 Feb; 22(1):73. PubMed ID: 38369461
[TBL] [Abstract][Full Text] [Related]
5. A decision analysis comparing three strategies for peritoneal lavage cytology testing in staging of gastric cancer in China.
He Q; Zhu J; Wang A; Ji K; Ji X; Zhang J; Wu X; Li X; Bu Z; Ji J
Cancer Med; 2020 Dec; 9(23):8940-8949. PubMed ID: 33047873
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of different screening strategies for helicobacter pylori infection in Iran: A model-based evaluation.
Yousefi M; Rezaei S; Khoshbaten M; Sarmasti M
Helicobacter; 2023 Dec; 28(6):e13027. PubMed ID: 37839058
[TBL] [Abstract][Full Text] [Related]
7. An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada.
Lewis D; Wong WWL; Lipscomb J; Horton S
Pharmacoeconomics; 2024 Apr; 42(4):393-407. PubMed ID: 38150120
[TBL] [Abstract][Full Text] [Related]
8. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
Callender T; Emberton M; Morris S; Eeles R; Kote-Jarai Z; Pharoah PDP; Pashayan N
PLoS Med; 2019 Dec; 16(12):e1002998. PubMed ID: 31860675
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.
Pashayan N; Morris S; Gilbert FJ; Pharoah PDP
JAMA Oncol; 2018 Nov; 4(11):1504-1510. PubMed ID: 29978189
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness analysis of a polygenic risk tailored breast cancer screening programme in Singapore.
Wong JZY; Chai JH; Yeoh YS; Mohamed Riza NK; Liu J; Teo YY; Wee HL; Hartman M
BMC Health Serv Res; 2021 Apr; 21(1):379. PubMed ID: 33892705
[TBL] [Abstract][Full Text] [Related]
11. The Clinical Impact and Cost-Effectiveness of Surveillance of Incidentally Detected Gastric Intestinal Metaplasia: A Microsimulation Analysis.
Thiruvengadam NR; Gupta S; Buller S; Awad I; Gandhi D; Ibarra A; Latorre G; Riquelme A; Kochman ML; Cote G; Shah SC; Saumoy M
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):51-61. PubMed ID: 37302442
[TBL] [Abstract][Full Text] [Related]
12. Endoscopy for Gastric Cancer Screening Is Cost Effective for Asian Americans in the United States.
Shah SC; Canakis A; Peek RM; Saumoy M
Clin Gastroenterol Hepatol; 2020 Dec; 18(13):3026-3039. PubMed ID: 32707341
[TBL] [Abstract][Full Text] [Related]
13. Benefits and harms of polygenic risk scores in organised cancer screening programmes: a cost-effectiveness analysis.
Xia C; Xu Y; Li H; He S; Chen W
Lancet Reg Health West Pac; 2024 Mar; 44():101012. PubMed ID: 38304718
[TBL] [Abstract][Full Text] [Related]
14. Cost-Utility Analysis of Early Detection with Ultrasonography of Differentiated Thyroid Cancer: A Retrospective Study on a Korean Population.
Baek HS; Ha J; Kim K; Bae JS; Kim JS; Kim S; Lim DJ; Kim CM
Endocrinol Metab (Seoul); 2024 Apr; 39(2):310-323. PubMed ID: 38590123
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of population-based screening for chronic obstructive pulmonary disease in China: a simulation modeling study.
Chen Q; Fan Y; Huang K; Li W; Geldsetzer P; Bärnighausen T; Yang T; Wang C; Chen S
Lancet Reg Health West Pac; 2024 May; 46():101065. PubMed ID: 38721063
[TBL] [Abstract][Full Text] [Related]
16. Is it worth it? Cost-effectiveness analysis of a commercial physical activity app.
Rondina R; Hong M; Sarma S; Mitchell M
BMC Public Health; 2021 Oct; 21(1):1950. PubMed ID: 34706689
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations.
Peters MLB; Eckel A; Seguin CL; Davidi B; Howard DH; Knudsen AB; Pandharipande PV
JCO Oncol Pract; 2024 Feb; 20(2):278-290. PubMed ID: 38086003
[TBL] [Abstract][Full Text] [Related]
18. Decision model analyses of upper endoscopy for gastric cancer screening and preneoplasia surveillance: a systematic review.
Canakis A; Pani E; Saumoy M; Shah SC
Therap Adv Gastroenterol; 2020; 13():1756284820941662. PubMed ID: 32728390
[TBL] [Abstract][Full Text] [Related]
19. Assessment of a SARS-CoV-2 population-wide rapid antigen testing in Italy: a modeling and economic analysis study.
Cavazza M; Sartirana M; Wang Y; Falk M
Eur J Public Health; 2023 Oct; 33(5):937-943. PubMed ID: 37500599
[TBL] [Abstract][Full Text] [Related]
20. Modeling the Cost-effectiveness of Esophageal Cancer Screening in China.
Li Y; Du L; Wang Y; Gu Y; Zhen X; Hu X; Sun X; Dong H
Cost Eff Resour Alloc; 2020; 18():33. PubMed ID: 32944005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
